IRGQ is an autophagy receptor that functions in MHC class I quality control and immune regulation 1. Unlike other immunity-related GTPases, IRGQ lacks GTPase activity but serves as a molecular adapter that specifically recognizes ubiquitinated misfolded MHC class I molecules and recruits them to autophagy machinery through binding to GABARAPL2 and LC3B 1. This interaction directs misfolded MHC class I toward lysosomal degradation, preventing accumulation of defective complexes at the cell surface 1. IRGQ-mediated degradation suppresses CD8+ T-cell responses by reducing surface presentation of aberrant MHC class I heavy chains, thereby promoting tumor immune evasion 12. In hepatocellular carcinoma, reduced IRGQ expression correlates with improved patient survival and enhanced anti-tumor immunity 12. IRGQ is regulated by the acetyltransferase ESCO1, which acetylates IRGQ and facilitates its ubiquitin-proteasome-mediated degradation in HPV-induced cervical cancer 3. These findings identify IRGQ as an immunomodulatory target for enhancing anti-tumor immunity through therapeutic inhibition 4.